胃癌晚期临床药物诊疗分析

Clinical analysis of drug treatment of advanced gastric cancer.

目的探讨晚期胃癌的药物治疗的疗效及反应。方法 19例患者均经病理学或细胞学确诊为晚期胃癌,均为复治病人。全部病例均有客观评价指标。采用伊立替康伊立替康(CPT-11)60 mg/m2,静脉滴注,第1、8、15天;奥沙利铂(LOHP)130 mg/m2,静脉滴注,第1天,28 d为一周期,连续用2周期后评价疗效及不良反应。结果 19例均完2个周期化疗,共接受42周期化疗,全部病例均可评价疗效及不良反应。无完全缓解(CR)病例,部分缓解(PR)7例(36.8%),无变化(NC)4例(21.1%),进展(PD)8例(42.6%),总有效率为36.8%,中位生存期8.6个月;不良反应主要是粒细胞减少,腹泻,恶心、呕吐,外周神经毒性,Ⅲ～IV度不良反应发生率低,粒细胞减少15.0%,腹泻4.2%。结论晚期胃癌患者药物治疗有确切疗效,不良反应轻,耐受性好。

Objective This paper discusses the treatment of advanced gastric cancer drug efficacy and response. Methods 19 patients were diagnosed by pathology or cytology of advanced gastric cancer, are complex medical treatment of people. All patients had an objective evaluation. With irinotecan CPT- 11 60 mg/m^2, intravenous drip1,8,15 d; oxaliplatin （LOHP） 130 mg/m^2, intravenous drip 1 d, 28 d as a cycle, 2 cycles of continuous use Evaluation of efficacy and adverse reactions. Results 19 patients completed 2 cycles of chemotherapy, received 42 cycles of chemotherapy, all patients could be evaluated the efficacy and adverse reactions. No case of CR, PR 7 cases（36.8% ）, NC 4 cases（21. 1% ）, PD 8 cases （42.6 % ）, the effective rate was 36.8 % , the median survival of 8.6 months; main adverse events were neutropenia, diarrhea, nausea, vomiting, peripheral neurotoxicity, Ⅲ -Ⅳ degree low incidence of adverse reactions, neutropenia 15.0%, diarrhea 4.2%. Conclusion Patients with advanced gastric cancer have the exact effect of drug therapy, adverse reactions, and well tolerated.